checkAd

     380  0 Kommentare VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX

    REGULATED INFORMATION

    GHENT, Belgium, 24 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V.

    The above shareholder notified Ablynx that it has exceeded the 10% threshold on 19 January 2017 and now holds 6,148,362 Ablynx shares, representing 10.07% of the current 61,076,074 outstanding Ablynx shares, an increase from a former position of 5.40% (August 2016).

    Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

    Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

    About Ablynx

    Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

    For more information, please contact
    Ablynx:
    Dr Edwin Moses
    CEO
    t:   +32 (0)9 262 00 07
    m: +32 (0)473 39 50 68
    e:  edwin.moses@ablynx.com

    Marieke Vermeersch
    Director IR & Corporate Communications
    t:   +32 (0)9 262 00 82
    m: +32 (0)479 49 06 03
    e:  marieke.vermeersch@ablynx.com
    Follow us on Twitter @AblynxABLX

    Ablynx media/analyst relations
    FTI Consulting:
    Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
    t: +44 20 3727 1000
    e: ablynx@fticonsulting.com





    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Ablynx via Globenewswire




    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX REGULATED INFORMATION GHENT, Belgium, 24 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose …